Alembic Pharmaceuticals Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹15,639 Cr
- P/E
- 20.96
- ROE
- 13.45%
- PEG
- 0.73
- Price to sales
- 2.00
- Debt to equity
- 0.25
- 52W high / low
- ₹961 / ₹647
- Sales growth (5Y)
- 6.37%
- EBITDA margin
- 14.99%
- Net profit margin
- 9.90%
- Promoter holding
- 69.87%
- Sales (last year)
- ₹7,784 Cr
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.
Guidance scorecard · Q1 FY27 call
What Alembic Pharmaceuticals Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
10–20%- US generics business expected to grow mid to high teens in FY27, upgraded from low to mid-teens earlier guidance.
- US branded specialty business projected to scale up over next few quarters and start contributing positively to profit from FY28 onwards.
- Around 15 new product launches planned in the US in next 9 months, with a similar number expected next year, supporting sustained US growth.
- ROW (Rest of World) markets expected to achieve around 15% growth in INR terms in FY27, with potential to surpass this depending on market conditions.
2 more points from Alembic Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Alembic Pharmaceuticals Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Alembic Pharmaceuticals incurred about INR400 crores of capex in the last year, contributing to higher depreciation/amortization.
- Preventive debottlenecking and maintenance upgrades were done in facilities (e.g., Ophthaline) to expand capacity without incremental capex.
- Strategic investments ongoing in R&D, manufacturing capabilities, and US branded business platform.
- Investments in US branded platform focus on building commercial capabilities and scaling specialty franchises; primarily marketing and field force costs with no manufacturing asset investments.
- Working on peptide development, regulatory filings, and portfolio development initiatives as part of R&D capital.
2 more points from Alembic Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Alembic Pharmaceuticals Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Ask what Alembic Pharmaceuticals Ltd said on the order book →
Full Q1 FY27 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Alembic Pharmaceuticals Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Alembic Pharmaceuticals Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Alembic Pharmaceuticals Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,406 | 1,486 | 1,595 | 1,631 | 1,517 | 1,562 | 1,648 | 1,693 | 1,770 | 1,711 | 1,910 | 1,876 | 1,848 |
| Expenses + | 1,203 | 1,287 | 1,387 | 1,364 | 1,257 | 1,325 | 1,409 | 1,433 | 1,498 | 1,430 | 1,594 | 1,585 | 1,620 |
| Operating Profit | 204 | 199 | 208 | 266 | 260 | 237 | 239 | 260 | 271 | 281 | 316 | 292 | 228 |
| OPM % | 14% | 13% | 13% | 16% | 17% | 15% | 15% | 15% | 15% | 16% | 17% | 16% | 12% |
| Other Income + | 1 | 12 | 10 | 3 | 4 | 2 | 30 | 10 | 14 | 6 | 8 | -27 | 2 |
| Interest | 14 | 14 | 16 | 15 | 11 | 13 | 19 | 22 | 25 | 24 | 24 | 23 | 23 |
| Depreciation | 74 | 66 | 68 | 69 | 69 | 69 | 71 | 70 | 69 | 74 | 76 | 80 | 89 |
| Profit before tax | 116 | 130 | 135 | 185 | 183 | 157 | 180 | 178 | 192 | 190 | 224 | 162 | 119 |
| Tax % | -31% | 7% | -1% | 2% | 3% | 14% | 15% | 23% | 18% | 19% | 18% | 18% | -70% |
| Net Profit + | 153 | 121 | 137 | 180 | 178 | 135 | 153 | 138 | 157 | 154 | 184 | 132 | 202 |
| EPS in Rs | 7.76 | 6.14 | 6.95 | 9.18 | 9.07 | 6.85 | 7.80 | 7.04 | 7.98 | 7.85 | 9.40 | 6.76 | 10.31 |
Financials of Alembic Pharmaceuticals Ltd
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,056 | 3,166 | 3,105 | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 6,229 | 6,672 | 7,345 |
| Expenses + | 1,653 | 2,159 | 2,490 | 2,488 | 3,061 | 3,383 | 3,913 | 4,432 | 4,970 | 5,296 | 5,664 | 6,226 |
| Operating Profit | 403 | 1,007 | 615 | 643 | 874 | 1,223 | 1,480 | 874 | 682 | 932 | 1,008 | 1,118 |
| OPM % | 20% | 32% | 20% | 21% | 22% | 27% | 27% | 16% | 12% | 15% | 15% | 15% |
| Other Income + | 4 | 7 | 2 | 7 | 9 | -39 | 87 | 56 | -2 | 28 | 56 | -12 |
| Interest | 4 | 5 | 5 | 3 | 18 | 27 | 16 | 18 | 50 | 56 | 79 | 94 |
| Depreciation | 44 | 72 | 83 | 105 | 115 | 157 | 183 | 287 | 275 | 273 | 279 | 319 |
| Profit before tax | 359 | 936 | 529 | 541 | 749 | 1,000 | 1,368 | 625 | 355 | 632 | 707 | 694 |
| Tax % | 21% | 23% | 23% | 22% | 21% | 20% | 19% | 17% | 4% | 3% | 18% | 3% |
| Net Profit + | 283 | 720 | 403 | 413 | 583 | 801 | 1,146 | 521 | 342 | 616 | 582 | 671 |
| EPS in Rs | 15.01 | 38.20 | 21.39 | 21.89 | 31.00 | 43.97 | 58.33 | 26.50 | 17.40 | 31.33 | 29.68 | 34.33 |
| Dividend Payout % | 23% | 9% | 19% | 18% | 18% | 23% | 24% | 38% | 46% | 35% | 37% | 35% |
Financials of Alembic Pharmaceuticals Ltd
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 38 | 38 | 38 | 38 | 38 | 38 | 39 | 39 | 39 | 39 | 39 | 39 |
| Reserves | 847 | 1,560 | 1,865 | 2,182 | 2,681 | 3,182 | 5,028 | 5,198 | 4,331 | 4,779 | 5,152 | 5,636 |
| Borrowings + | 264 | 114 | 89 | 708 | 1,128 | 1,747 | 584 | 717 | 722 | 513 | 1,258 | 1,430 |
| Other Liabilities + | 493 | 718 | 698 | 1,013 | 931 | 1,022 | 1,058 | 1,167 | 1,090 | 1,114 | 1,324 | 1,658 |
| Total Liabilities | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 | 7,773 | 8,763 |
| Fixed Assets + | 547 | 708 | 799 | 993 | 1,158 | 1,552 | 1,788 | 1,798 | 2,398 | 2,547 | 2,524 | 3,130 |
| CWIP | 83 | 93 | 396 | 1,010 | 1,551 | 1,846 | 2,183 | 2,304 | 601 | 524 | 837 | 634 |
| Investments | 2 | 87 | 50 | 42 | 49 | 18 | 236 | 118 | 96 | 93 | 127 | 141 |
| Other Assets + | 1,009 | 1,541 | 1,444 | 1,896 | 2,019 | 2,573 | 2,502 | 2,902 | 3,087 | 3,281 | 4,285 | 4,858 |
| Total Assets | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 | 7,773 | 8,763 |
Financials of Alembic Pharmaceuticals Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 172 | 948 | 329 | 312 | 812 | 449 | 1,463 | 552 | 724 | 803 | 88 | 783 |
| Cash from Investing Activity + | -256 | -307 | -486 | -884 | -756 | -731 | -840 | -372 | -448 | -321 | -568 | -506 |
| Cash from Financing Activity + | 87 | -224 | -129 | 503 | 59 | 155 | -597 | -217 | -262 | -438 | 444 | -164 |
| Net Cash Flow | 3 | 417 | -286 | -69 | 115 | -127 | 26 | -37 | 14 | 45 | -37 | 113 |
| Free Cash Flow | -52 | 647 | 348 | -495 | 49 | -285 | 804 | 128 | 282 | 487 | -466 | 290 |
| CFO/OP | 60% | 114% | 73% | 70% | 112% | 56% | 115% | 77% | 115% | 88% | 16% | 79% |
Financials of Alembic Pharmaceuticals Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 40 | 40 | 61 | 45 | 69 | 24 | 56 | 68 | 60 | 77 | 73 |
| Inventory Days | 196 | 266 | 269 | 302 | 356 | 417 | 431 | 406 | 315 | 350 | 466 | 462 |
| Days Payable | 166 | 264 | 213 | 313 | 237 | 220 | 194 | 178 | 145 | 157 | 179 | 154 |
| Cash Conversion Cycle | 94 | 42 | 96 | 51 | 164 | 266 | 261 | 283 | 237 | 253 | 363 | 381 |
| Working Capital Days | 32 | 36 | 61 | 69 | 24 | 50 | 73 | 74 | 77 | 88 | 87 | 88 |
| ROCE % | 38% | 66% | 29% | 22% | 23% | 24% | 26% | 11% | 7% | 13% | 13% | 13% |
Guidance history
How Alembic Pharmaceuticals Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q4 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q3 FY26 call → | 10–20% | Flat | None planned | — | — |
| Q2 FY26 call → | 10–20% | Up 2%+ | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
28 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −11.8% | 47% |
| Last 6 months | +5.3% | 61% |
| Last 3 months | −1.0% | 62% |
The price is 36.2% below its all-time high of ₹1,245.15 (2 Aug 2024). Stocks more than 20% below their peak have their score halved, so 55 became 28.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Alembic Pharmaceuticals Ltd: 0.4 × 47 + 0.4 × 61 + 0.2 × 62 = 55, halved to 28 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Alembic Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY